AstraZeneca Pharma receives marketing permission for Osimertinib

09 Aug 2018 Evaluate

AstraZeneca Pharma India has received Import and Market permission - additional indication for osimertinib (Tagrisso) Tablet 40 mg and 80 mg, as 1st line treatment for EGFRm advanced Non-Small Cell Lung Cancer (NSCLC) by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of osimertinib in India for 1st line treatment.

Osimertinib is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitutions mutations.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma I Share Price

8908.70 -254.05 (-2.77%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×